BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20646020)

  • 1. Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines.
    Sigurdsson K
    Cytopathology; 2010 Aug; 21(4):213-22. PubMed ID: 20646020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
    Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL
    Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical screening in the era of HPV vaccination.
    Farnsworth A
    Cytopathology; 2010 Aug; 21(4):211-2. PubMed ID: 20646019
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
    Schindeler S; Morrell S; Zuo Y; Baker D
    J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic HPV vaccination for women over 18 years of age.
    Adams M; Jasani B; Fiander A
    Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.
    Wright TC; Bosch FX; Franco EL; Cuzick J; Schiller JT; Garnett GP; Meheus A
    Vaccine; 2006 Aug; 24 Suppl 3():S3/251-61. PubMed ID: 16950014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Can human papillomavirus testing and vaccination prevent cervical cancer?].
    Lie AK; Bjørge T; Helland A; Hagen B; Skjeldestad FE; Hagmar B; Thoresen S
    Tidsskr Nor Laegeforen; 2001 Oct; 121(25):2947-51. PubMed ID: 11715778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial.
    Gudmundsdóttir T; Tryggvadóttir L; Allende M; Mast TC; Briem H; Sigurdsson K
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):345-50. PubMed ID: 12716319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
    Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.
    Wheeler CM
    Nat Clin Pract Oncol; 2007 Apr; 4(4):224-35. PubMed ID: 17392713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995.
    Sigurdsson K
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):478-85. PubMed ID: 10376856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.